Fresenius

(IN BRIEF) Fresenius Kabi, an operating company of Fresenius, has announced that the U.S. FDA has approved a rituximab biosimilar developed by Dr. Reddy’s Laboratories for the U.S. market. Under an exclusive commercialisation agreement, Fresenius Kabi holds the U.S. commercialisation … Read the full press release →

(IN BRIEF) Fresenius Medical Care has introduced TherapyWise™, a cloud-based analytics capability available within NxView™ 4.0, its FDA 510(k)-cleared software platform for use with the NxStage® System One™ in the United States. TherapyWise provides retrospective, programme-level insight into kidney replacement … Read the full press release →

(IN BRIEF) Fresenius has launched the Pedismof® range in Europe, a new ready-to-use three-chamber bag solution for pediatric parenteral nutrition developed by Fresenius Kabi. The range provides age-specific formulations for preterm and term neonates, infants, children and adolescents, supporting standardized … Read the full press release →

(IN BRIEF) Fresenius Medical Care has launched kinexus worldwide as a unified digital platform designed to support home dialysis programs by combining remote therapy monitoring, prescription management, and supply-ordering workflows in one integrated system. The platform supports both peritoneal dialysis … Read the full press release →

(IN BRIEF) Fresenius Medical Care has announced a new share buyback program with a total volume of around EUR 1 billion, to be executed in tranches over 12 months from the start of the program. The buyback is expected to … Read the full press release →

(IN BRIEF) Fresenius has announced a strategic investment in Avelios Medical in collaboration with SAP, further advancing their partnership to create a digital, AI-enabled healthcare ecosystem in Europe. The initiative focuses on developing a next-generation, cloud-based hospital information system that … Read the full press release →

(IN BRIEF) Fresenius and SAP have announced plans to form a strategic partnership to accelerate digital innovation in healthcare and establish a sovereign, interoperable, and AI-supported healthcare ecosystem. By combining Fresenius’ global healthcare expertise with SAP’s digital platforms and AI … Read the full press release →

(IN BRIEF) Fresenius’ mAbxience has partnered with HP Inc. to co-develop an AI and digital-twin solution that can model and optimise biopharmaceutical manufacturing. The technology uses real plant data to simulate production scenarios, helping increase reliability, stabilise yields and shorten … Read the full press release →

(IN BRIEF) Fresenius Kabi has launched its denosumab biosimilars Conexxence® and Bomyntra® across Europe following European Commission approval in July 2025 for all indications of their reference medicines Prolia® and Xgeva®. The products target a range of conditions including osteoporosis, … Read the full press release →

(IN BRIEF) Fresenius Medical Care will present multiple studies at ASN Kidney Week 2025, highlighting how hemodiafiltration (HDF) enhances clinical outcomes and how artificial intelligence is transforming kidney care. One of the featured oral presentations links HDF to a reduced … Read the full press release →

(IN BRIEF) Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the Middle East and North Africa—once approved. Vedolizumab treats Crohn’s disease and ulcerative colitis, and PB016 references Takeda’s Entyvio®. The transaction … Read the full press release →

(IN BRIEF) The European Commission has approved Fresenius Kabi’s denosumab biosimilars, Conexxence® and Bomyntra®, for all uses of the originator product. These include osteoporosis treatment for postmenopausal women and at-risk men, mitigation of treatment-related bone loss, prevention of skeletal complications … Read the full press release →

(IN BRIEF) Fresenius Kabi’s Santiago de Besteiros plant in Portugal has secured BSI Kitemark™ Certification for Minimized Risk of AMR in its Ceftriaxone production, confirming compliance with the AMR Industry Alliance’s Antibiotic Manufacturing Standard. Key measures include stringent controls to … Read the full press release →

(IN BRIEF) Fresenius Medical Care has received FDA 510(k) clearance for its updated 5008X CAREsystem with additional features, enabling the introduction of high-volume hemodiafiltration therapy across the U.S. This new therapy, proven to reduce mortality rates by 23% in patients, … Read the full press release →

(IN BRIEF) Fresenius Medical Care will showcase a variety of new research at the 62nd Congress of the European Renal Association (ERA) in Vienna, focusing on advancements in kidney care, artificial intelligence, fluid management, and hemodiafiltration. Key studies include the … Read the full press release →

(IN BRIEF) South African clinical dietitian Lizl Veldsman has won the 2025 Harry M. Vars Award from ASPEN for her innovative ICU study supported by Fresenius Kabi. The study examined the impact of intravenous protein and in-bed cycling on muscle … Read the full press release →

(IN BRIEF) The Fresenius healthcare group is constructing a new facility, KabiLab D20, at Daimlerstrasse 20 on its Bad Homburg campus, set to cover 5,000 m². This modern laboratory and office building will feature state-of-the-art laboratories, 90 shared workstations, meeting … Read the full press release →

(IN BRIEF) Quest Diagnostics has agreed to acquire select assets from Fresenius Medical Care’s Spectra Laboratories, expanding its portfolio with dialysis-related laboratory and water testing services. This collaboration will enhance the care and efficiency of dialysis services across the U.S., … Read the full press release →

(IN BRIEF) A study by the Technical University of Munich (TUM), LMU Hospital Munich, and Helmholtz Munich found that while intermittent fasting benefits adult mice by improving insulin sensitivity, it harms beta cell development in adolescent mice, which could have … Read the full press release →

(IN BRIEF) Fresenius has signed a five-year global contract with Microsoft to enhance IT collaboration and security for its global workforce. Beginning in June 2025, the agreement will include tools such as Microsoft Defender, Microsoft 365, SharePoint, OneDrive, and Microsoft … Read the full press release →